Vaxcyte, Inc. PCVX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s total liabilities & equity?
- Vaxcyte, Inc. (PCVX) reported total liabilities & equity of $3.35B in Q1 2026.
- How has Vaxcyte, Inc.'s total liabilities & equity changed year-over-year?
- Vaxcyte, Inc.'s total liabilities & equity decreased by 0.9% year-over-year, from $3.38B to $3.35B.
- What is the long-term trend for Vaxcyte, Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), Vaxcyte, Inc.'s total liabilities & equity has grown at a 50.2% compound annual growth rate (CAGR), from $392.83M to $3B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.